Chongqing Zhifei Biological Products Co.,Ltd.

2002 The predecessor company was integrated into Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), and entered biological products industry.
2003 Beijing Luzhu Biopharmaceutical Co., Ltd. was founded and the company started the construction of its R&D and manufacturing facilities.
2004 Chongqing Zhiren Biotech Co., Ltd. was founded, which mainly engages in distribution of biological products and generic drugs.
2006 The first self-developed product — Meningococcal Group A and C Conjugate Vaccine (MenAC Conj Vaccine) received market approval.
2007 Self-developed product — Group ACYW135 Meningococcal Polysaccharide Vaccine (MenACYW135 Ps Vaccine) received market approval.
2008 MenAC Conj Vaccine and MenACYW135 Ps Vaccine launched onto the domestic market.
2009 Zhifei was restructured into a joint-stock company.
2010 Zhifei successfully went listed on Chinext, Shenzhen Stock Exchange.
2012 In 2012, Zhifei launched an independently developed new product - Hib vaccine.
2014 In 2014, MenAC-Hib, independently-developed by Zhifei, first product of its kind worldwide was launched filling the blank of combination vaccine of meningococcus and Haemophilus influenzae.
In the same year, Zhifei founded Chongqing Zhirui Investment Co., Ltd., an equity investment company, with self-funding and the contribution of Mr. Jiang Rensheng, the controlling shareholder and actual controller of Zhifei, to make presence in a broader biological industry.
2015 In 2015, Zhifei signed a strategic cooperation agreement with Institut Pasteur of Shanghai of Chinese Academy of Sciences.
2016 In 2016, Zhifei founded Zhifei Airport (Beijing) International Trade Co., Ltd.
2017 In 2017, Zhifei renewed its distribution and promotion cooperation agreement with Merck Sharp & Dohme of USA (MSD) to import 4-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 20-45 years.

In 2018, Zhifei signed a supplementary agreement with MSD to import 9-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 16-26 years.
Zhifei donated RMB10 million to support the establishment of the first Escort Disease Control Fund in China.



The Company get completed the clinical and production site verification for its independently developed Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) and Mycobacterium Vaccine (for TB infected population use) and increased the registered capital of its wholly-owned subsidiaries Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. to RMB1,332,156,900 and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. to RMB765 million; Chairman Jiang Rensheng was awarded the honorary title of outstanding builder of socialism with Chinese characteristics.


Recombinant mycobacterium tuberculosis fusion protein (EC, Ekear ®) was issued the drug registration approval document in April;

The recombinant novel coronavirus vaccine (CHO cells) jointly developed by the company and the Institute of Microbiology Chinese Academy of Sciences officially obtained the Clinical Trial Notice of the National Medical Products Administration in June. 


On March 10, the novel coronavirus vaccine (CHO cells) jointly developed by Zhifei Longcom and the Institute of Microbiology, Chinese Academy of Sciences, was granted the emergency use license in China. It became the first internationally approved recombinant protein subunit vaccine in the world.